Apthera | GenomeWeb

Apthera

RXi also broke out its financial results for 2010 in the filing, reporting a drop in its net loss amid lower research and development spending. The company said, however, that it anticipates its expenses to increase going forward on NeuVax-related expenses.

RXi bought the firm for around $7.2 million in order to accelerate its move from a research-based company to a clinical-stage one.

RXi's pending acquisition of Apthera will also enable the company to explore the combination of its RNAi technologies with Apthera's peptide know-how, RXi's CEO said.

The deal gives RXi a late-stage peptide immunotherapy for breast cancer and marks a shift in strategy that nudges the company from its previous focus as a pure-play RNAi shop.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.